Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Rock Springs Capital Management LP

Rock Springs Capital Management LP trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 305,000 shares of the biotechnology company's stock after selling 20,000 shares during the quarter. Ascendis Pharma A/S accounts for about 1.6% of Rock Springs Capital Management LP's portfolio, making the stock its 19th largest position. Rock Springs Capital Management LP owned approximately 0.50% of Ascendis Pharma A/S worth $41,989,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Legato Capital Management LLC increased its holdings in shares of Ascendis Pharma A/S by 7.5% during the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after acquiring an additional 134 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S in the third quarter worth $30,000. GAMMA Investing LLC lifted its stake in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after buying an additional 214 shares during the period. Finally, Blue Trust Inc. grew its holdings in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares during the last quarter.

Ascendis Pharma A/S Price Performance

ASND traded up $3.70 during midday trading on Friday, reaching $164.15. 560,181 shares of the company's stock were exchanged, compared to its average volume of 488,446. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37. The stock has a market capitalization of $10.01 billion, a PE ratio of -23.12 and a beta of 0.54. The business's 50-day moving average price is $153.78 and its 200 day moving average price is $138.90.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. As a group, analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on ASND shares. Royal Bank of Canada began coverage on shares of Ascendis Pharma A/S in a report on Wednesday, April 16th. They issued an "outperform" rating and a $205.00 price target on the stock. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research report on Tuesday, February 18th. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Finally, UBS Group assumed coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price for the company. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $204.67.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.